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Abstract
Background: ANCA-associated small vessel vasculitides (AAV) are prone to cycles of relapse and remission.
Renal involvement manifests as glomerulonephritis with microscopic haematuria, red blood cell casts, proteinuria
and variable decrease in renal function. Remission of renal vasculitis is defined as stabilization in serum creatinine
(Creat) and resolution of haematuria while controversy exists about persistence of haematuria (during apparent
disease-remission) since it may indicate smouldering disease-activity or should be considered as renal flare.
Objective: To clarify the course of haematuria after diagnosis and induction therapy and its possible predictive
value of long term renal function.
Design: Retrospective cohort study.
Participants: 96 consecutive AAV-patients with renal involvement diagnosed and treated with systemic AAV
between 1st of January 2000 to 31th December 2007 were followed for 60 months.
Main measures: Collected data were Creat, CRP (mg/ml), eGFR ml/min/1.73 m2, creatinine-excretion in
collected 24 h urine (Ucreat/24 h), proteinuria (Uprot), ratio of proteinuria/ creatinine in 24 h urine (Uprot/creat) and
haematuria. Data were analysed for the complete study population and compared for MPO-ANCA and PR3-ANCA.
Key results: At twelve months after diagnosis, haematuria was no longer detectable in 92% of all patients. In the
PR3-ANCA group, haematuria disappeared after 13 months, while in the MPO-ANCA group haematuria persisted in
19% of the patients. On average, haematuria disappeared almost simultaneously with stabilisation of the renal
function.
Conclusion: Haematuria persists for many months after diagnosis and disappears usually simultaneously with
stabilisation of kidney function. There was no relation between persistence of haematuria for over 12 months and
renal function during follow up. Haematuria probably acts as a sensitive marker for absence of inflammatory
glomerular disease activity in most patients with systemic AAV and renal involvement. It is disappearance coincide
with stabilisation of renal function and remission of the disease in almost all patients. However, if it persists, it is not
predictive for worsening renal function nor for relapse. Proteinuria does not seem to be a reliable marker for renal
disease remission.
Keywords: Haematuria; Prediction; ANCA; Vasculitis; Relapse
Introduction
The small-vessel vasculitides consist of a heterogeneous group of
uncommon systemic multi-organ disorders that are prone to cycles of
remission and relapse [1]. These vasculitides include Granulomatosis
with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and
eosinophilic Granulomatosis with Poly-Angiitis (eGPA) [1]. These
diseases are strongly associated with the presence of antineutrophil
cytoplasmic autoantibodies (ANCA): more than 90% of patients have
ANCA against proteinase 3 (PR3-ANCA) and myeloperoxidase
(MPO-ANCA) [1-4]. Renal involvement is the most common severe
manifestation in patients with ANCA-associated vasculitis (AAV),
manifesting as glomerulonephritis with microscopic haematuria, red
blood cell casts, proteinuria and a variable level of renal failure [1-3].
Since AAV is a chronic disease with disease-free periods and
relapses, therapy usually starts with induction therapy based on
cyclophosphamide and corticosteroids, inducing remission in weeks to
months in most patients [5,6]. Remission of renal vasculitis is defined
as decrease or resolution of clinical disease manifestations and
subsequent stabilisation in serum creatinine; thoughts about the
resolution of haematuria and/or proteinuria are less clear [1]. It is
suggested that the persistence of haematuria in AAV patients (in
apparent remission) reflects a kind of smouldering disease-activity or
should be considered as a renal flare that might benefit from increasing
immunosuppressive therapy [1].
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However, controversy about the meaning or the time course of
haematuria in patients with ANCA-associated vasculitis exists. The
aim of this study was, therefore, to clarify the course of haematuria
after diagnosis and induction therapy and its possible predictive value
on long-term renal function. Since PR3- and MPO-ANCA associated
vasculitides have distinct clinical and Histopathological differences,
comparison was made between these different entities.
Methods
Study population
We studied 96 consecutive patients newly diagnosed with systemic
AAV and renal involvement and treated in the period 1st of January
2000 to 31th December 2007 within our hospital. Patients were
followed on regular outpatient clinic visits for at least 18 months
following start of therapy; thereafter follow up was completed 60
months after diagnosis, until death or loss to follow-up.
Due to insufficient follow-up data on urinary parameters in the first
18 months three patients were removed from the analysis leaving 93
patients in the final analysis.
Study design and definitions
During routine follow up, data were collected at different moments
during the disease period, i.e. 0, 2 and 4 weeks and from month 2-18 at
each visit on the outpatient clinic (at least every three months).
Collected data were serum creatinine, CRP mg/l and 24 hour urine
collection for creatinine and protein (Ucreat mmol/24 h, Uprot gr/24
h). The Uprot/creat was calculated with the formula: proteinuria/
creatinine-excretion, gr/24 h, in collected 24 h urine. In addition, a
freshly voided urine specimen was checked for presence of haem, and
if positive, microscopic analysis of the urinary sediment was
performed to quantify haematuria. A number less than 5 erythrocytes
per high powered field (corresponds to approximately 25/ul) was
regarded as non-significant or negative while 5 or more per field was
regarded as significant haematuria. Malignancy of urogenital tract was
ruled out in all cases. Remission of haematuria was defined as a normal
value; it means a negative stick or less than 5 erytrocytes/htf, for at
least 3 consecutive months or a longer lasting course with one single
abnormal value. The first of these 3 normal values was defined as the
‘month of remission’. Serum creatinine was used to define a clinical
stable renal function. Renal function was considered stable at the
lowest serum creatinine value and a stable serum creatinine for 3
consecutive months combined with stabilised clinical characteristics.
Proteinuria was assessed as the ratio of urinary protein (g/l) and
creatinine (mmol/l). Remission of Uprot/creat (g/mmol) was defined
as the lowest value during follow up followed by at least 3 months of
stable values. Long term persistence of haematuria, proteinuria and
unstable serum creatinine were defined as not reaching the definition
for remission at 12 months. The course of the haematuria within the
whole study population, as well as the differences in haematuria course
for MPO-ANCA and PR3-ANCA patients were analysed. The same
was done for the course of serum creatinine and the ratio of Uprot/
Creat. Third, the moments of remission between serum creatinine and
haematuria as well as serum creatinine and the ratio Uprot/Creat were
compared. Finally, a comparison was made for the long term renal
function. Primary outcome of this study was the course of haematuria
during treatment; secondary outcomes were renal function (serum
creatinine), proteinuria and change in renal function during follow up.
Statistical analyses
Descriptive statistics were generated and analysed using SPSS20.
Outcomes were analysed with Mann-Whitney U test or Chi-square
test. The course of haematuria, Creat and the Uprot/Creat were




Fifty-six patients were PR3-ANCA positive (58%), 37 were MPO-
ANCA-positive (39%) one was HNE-positive and two patients were
ANCA negative. Baseline characteristics were compared for PR3-
ANCA and MPO-ANCA positive patients (Table 1). Of all the patients,
65 were male (68%). Median age was 63 (range 51.3-72.5) years. In 38
patients (40%) the diagnosis was renal biopsy-proven. Twenty-four
patients (26%) died within the 60 months of follow-up after diagnosis
of which 15 (16%) during the first 18 months after diagnosis.
Significant differences between PR3-ANCA positive and MPO-ANCA
positive patients as expected, were found regarding sex, age, serum




(n= 37) (n= 56)
Sex (M/F) 19/18 44/12 0.006b
Age (years) 66 (56-75) 60 (45-70) 0.03b
Haematuria (%) 100 100 0.72
Creat (μmol/l) 257 (144-626) 119 (100-328) 0.007b
eGFR (ml/min/1,73 m2) 17 (7-34) 56 (17-69) 0.001b
Clearance 20 (7-43) 59 (13-85) 0.002b
CRP (mg/l) 48 (14-120) 120 (50-169) 0.001b
UCreat (mmol/24 u) 7.4 (5.2-10.2) 9.9 (5.7-12.8) 0.05b







Table 1: Baseline patient characteristics. A-median (IQR) unless
otherwise specified; B-Statistically significant
Haematuria
At baseline haematuria was present in all patients. At 1, 3, 6, 12 and
18 months of follow up, haematuria was present in 58%, 28%, 22%,
10% and 6% of the patients respectively. Haematuria had disappeared
in 72% and in 92% after 6 and 12 months respectively. When
comparing PR3-ANCA and MPO-ANCA at 6 and 12 months,
haematuria had disappeared in 80% and 98% for PR3-ANCA and 57%
and 81% in MPO-ANCA (log rank p=0.005). After 13 months, in all
PR3-ANCA positive patients haematuria was no longer detectable,
while it persisted in 19% of the MPO-ANCA positive patients (Figure
1).
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Figure 1: A: Survival curve of haematuria for complete study
population, 1B :PR3- versus MPO-ANCA positive patients ((Log
rank p=0.003).
Figure 2: A) Survival cure of, serum creatinine for complete study
population; 2B: PR3- versus MPO-ANCA positive patients.
Figure 3: A) Survival curve of Uprot/Creat in collected 24h urine for
complete study population; 3B. PR3- versus MPO-ANCA positive
patients.
Serum creatinine
Within 6 and 12 months after diagnosis, serum creatinine stabilized
in 84% and 94% respectively. Comparing PR3-ANCA and MPO-
ANCA at 6 and 12 months, serum creatinine was stable in 86% and
96% for PR3-ANCA and 80% and 88% in MPO-ANCA respectively
log rank p=0.90 ( Figure 2).
Haematuria and serum creatinine
The mean difference between a stable kidney function and the
disappearance of haematuria was 0.036 months (SD 2.79). For the
PR3-ANCA group this was 0.42 months (SD 2.72) and for MPO-
ANCA -0.98 months (SD 2.80). This indicates that, after diagnosis, on
average the haematuria disappearance and stabilisation of serum
creatinine coincide in time. A crosstab was generated to compare the
patients with haematuria and unstable serum creatinine for more than
12 months. No correlation between these two parameters was found
(Fisher’s Exact p=1.000); therefore no further prediction can be made
based on the findings of the first 12-18 months after diagnosis.
Haematuria nor the persistence after 6 and 12 months were predictors
for renal function over time nor for relapse until 60 months after
diagnosis, not even when separately analysed for ANCA-specificity.
Proteinuria
After a follow-up period of 6 and 12 months from diagnosis, the
Uprot/creat reached stabilisation in 35% and 74% of the patients
respectively. Comparing PR3-ANCA and MPO-ANCA at 6 and 12
months, Uprot/creat was stable in 34% and 72% for PR3-ANCA and
36% and 79% in MPO-ANCA respectively log rank p=0.88 (Figure 3).
Figure 4: Survival curve for complete study population.
Figure 5: Relapse free survival curve for complete study population
Proteinuria and serum creatinine
The mean difference between a stable kidney function and the stable
Uprot/creat ratio was -6.1 months (SD 4.93) for the total study
population. This indicates that serum creatinine stabilises on average
about 6 months earlier than proteinuria does. There was no difference
between the PR3-ANCA group (-6.0 months (SD 4.9)) and the MPO-
ANCA group (-6.4 months, SD 5.0). Patients survival, relapse-free
survival and long-term renal function. During long term follow up,
survival rates were 88% at 12 months and 75% at 60 months. There was
no difference in patient survival between PR3 and MPO-ANCA
positive patients, p=0.36 (Figure 4).
At 60 months, a third of all patients had experienced a relapse: as
expected, these relapses happened more often in the PR3-ANCA
positive patients, 16% in MPO-patients (n=6) and 30% in PR3-patients
(n=17), with a trend towards significance, p=0.12 (Figure 5). During
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long term follow up, overall renal function did not change significantly
over time without difference for ANCA-specificity or experiencing
relapses (Figure 6).
Figure 6: Delta serum creatinine 6-12, 12-18 and 18-60 months.
Discussion
In this retrospective study of 96 patients with pauci-imune
glomerulonephritis it was questioned whether microscopic haematuria
in patients with renal vasculitis in clinical remission could represent
chronic glomerular injury from prior episodes of disease-activity or
may represent new glomerular pathology [1]. We found that in
general, haematuria disappears between three and six months after
diagnosis and start of induction therapy and that the disappearance
coincides in time with stabilisation of renal function. Nevertheless, as
reflected by persisting proteinuria, microscopic injury may persists for
a longer period. During follow up, persistence of haematuria is neither
associated with worsening renal function nor predictive for relapse.
In prior reports, Magrey et al. suggested that a subset of patients
with GPA and glomerulonephritis may have persistent microscopic
haematuria from glomerular injury and not from active disease, stating
that patients with GPA and glomerulonephritis probably achieved
enduring remission, allowing withdrawal of medication, despite
continued microscopic haematuria with or without RBC casts [3].
Franssen et al. described resolution of haematuria within four months
after start of treatment in a large cohort study of MPO-ANCA positive
patients. None of the treated patients who developed chronic renal
failure had haematuria at any time during follow-up but in addition
each of the relapses encountered during follow up was associated with
recurrence of haematuria [7]. In our cohort of 96 patients with
systemic AAV and renal involvement, after follow-up of 6 months,
haematuria had disappeared in 72% of the whole study population.
However, only in the PR3-ANCA positive patients, haematuria became
negative at follow-up of 13 months, while in the MPO-ANCA positive
patients, haematuria persistent in a small group (19%) of patients.
There was no association with the persistence of haematuria and
decline in renal function or relapse in these patients.
However, this difference between PR3-ANCA and MPO-ANCA-
positive patients was significant, p=0.003, which again may underscore
the conclusion that PR3-AAV and MPO-AAV are distinct diseases. On
average the haematuria disappeared almost simultaneously with
stabilisation of the renal function and only a small minority had on-
going haematuria 6 months after diagnosis. The proteinuria persisted
for about 6 months longer compared to stabilisation of the renal
function. On these grounds, one can conclude that the disappearance
of haematuria can act as a marker for stabilisation of renal function
and absence of on-going inflammatory disease activity. Proteinuria
therefore cannot be used as a marker for quiescence of renal disease.
During long term follow up, haematuria or the persistence appeared
not to be of predictive value for renal function nor for relapses and can
certainly not act as a guidance for therapy. There are some
considerations: a number of missing values during follow up could
have influenced the analyses, for instance in defining date of remission
in these particular patients. In addition, it is debatable whether the
study population is representative for the population of patients with
systemic AAV since in our tertiary referral centre mostly complex
patients are treated who sometimes did not immediately responded to
standard induction therapy. This can have had influence on outcomes.
Nevertheless, considering the fact that even complex patients are also
included in these analyses, we think that our findings on haematuria,
remission and predictive value could be generalizable.
In conclusion, we found that haematuria probably acts as a sensitive
marker for absence of inflammatory glomerular disease activity in
most patients with systemic AAV and renal involvement. It’s
disappearance coincide with stabilisation of renal function and
remission of the disease in almost all patients. However, if it persists, it
is not predictive for worsening renal function nor for relapse. This
means that one should monitor these patients closely, but there is not
enough evidence that supports escalation of immunosuppressive
medication based on persistence of haematuria alone. Furthermore,
since microscopic injury as indicated by proteinuria persists for longer
duration, proteinuria does not seem to be a reliable marker for renal
disease remission.
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